STAT3 and prostate cancer: In addition, PMN-MDSCs with high levels of STAT3 activity and ARG1 expression are strongly related to prostate cancer progression, and STAT3 blockade impairs the immunosuppressive effect of PMN-MDSCs on effector T-cell activity [140].